Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urology Journal Pub Date : 2024-10-12 DOI:10.22037/uj.v21i.8055

Taha Cetin, Serdar Celik, Sinan Sozen, Haluk Ozen, Bulent Akdogan, Guven Aslan, Sumer Baltaci, Evren Suer, Yıldırım Bayazit, Volkan Izol, Talha Muezzinoglu, Fatih Gokalp, Ilker Tinay

{"title":"Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort.","authors":"Taha Cetin, Serdar Celik, Sinan Sozen, Haluk Ozen, Bulent Akdogan, Guven Aslan, Sumer Baltaci, Evren Suer, Yıldırım Bayazit, Volkan Izol, Talha Muezzinoglu, Fatih Gokalp, Ilker Tinay","doi":"10.22037/uj.v21i.8055","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications.Materials and methods: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype.Results: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM.Conclusion: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.","PeriodicalId":23416,"journal":{"name":"Urology Journal","volume":" ","pages":"320-324"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22037/uj.v21i.8055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications.

Materials and methods: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype.

Results: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM.

Conclusion: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.

查看原文本刊更多论文

嗜铬细胞肾细胞癌与透明细胞肾细胞癌的肿瘤学结果：当代土耳其患者队列的结果。

目的：比较肾细胞癌（RCC）中常见的透明细胞RCC（ccRCC）和较少见的疏色细胞RCC（chRCC）的肿瘤治疗效果，并确定影响土耳其RCC亚分类患者生存的因素：对土耳其泌尿肿瘤协会（TUOA）泌尿肿瘤数据库-肾（UroCaD-K）中根治性或部分肾切除术后病理确诊为RCC的患者进行回顾性研究。研究对象包括ccRCC和chRCC患者。本研究的主要结果是每种组织学亚型的无复发生存率（RFS）、总生存率（OS）和癌症特异性生存率（CSS）：结果：研究回顾了TUOA UroCaD-K中5300名患者的数据，共有2560名患者（ccRCC组2225人，chRCC组335人）被纳入最终分析。在两组患者的比较中，ccRCC患者的肿瘤大小在放射学和病理学上都更大（P=0.019 vs 0.002）。ccRCC亚组的无复发生存率（RFS）、总生存率（OS）和癌症特异性生存率（CSS）更低。在对风险因素进行评估时，发现病理分期、局部浸润和 Fuhrmann 分级对 ccRCC 的复发有显著影响。年龄、体重指数和病理分期是影响总死亡率（OM）的风险因素。病理肿瘤大小是chRCC复发的独立风险因素，而年龄是唯一影响OM的参数。结论：在土耳其患者群体中，chRCC的肿瘤学数据以及OS、CSS和RFS率均优于ccRCC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urology Journal UROLOGY & NEPHROLOGY-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： As the official journal of the Urology and Nephrology Research Center (UNRC) and the Iranian Urological Association (IUA), Urology Journal is a comprehensive digest of useful information on modern urology. Emphasis is on practical information that reflects the latest diagnostic and treatment techniques. Our objectives are to provide an exceptional source of current and clinically relevant research in the discipline of urology, to reflect the scientific work and progress of our colleagues, and to present the articles in a logical, timely, and concise format that meets the diverse needs of today’s urologist. Urology Journal publishes manuscripts on urology and kidney transplantation, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. Accordingly, original articles, case reports, and letters to editor are encouraged.